Drug Trial Radar · NCT06606730
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,454
Planned (sponsor's estimate)
Start
Jul 23, 2025
Primary completion
Jan 1, 2033
Study completion Jun 1, 2039
Sponsor
- Lead sponsor
- UNICANCERAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
OPT-PEMBRO trial is a pragmatic, multicentre, international, prospective, non-inferiority, two-arms, randomised (1:1), open-label, Phase III clinical study. The main goal of this research is to determine if patients with triple-negative breast cancer, who experience a complete response after neoadjuvant treatment, have the same chance of avoiding cancer recurrence whether they stop pembrolizumab or continue taking it for an additional 6 months. This research will also take into account patients tolerance to treatment and quality of life.
Conditions
- Breast Cancers
- Triple Negative Breast Cancer (TNBC)
Interventions
PembrolizumabDrug
Administration of pembrolizumab for 6 months
DeescalationOther
Patients will be followed up according to standard practice for 4 years
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence-free survivalTime frame: From randomization to disease progression or death, up to 8 years.
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Cliniques Universitaires Saint Luc Brussels
Brussels, Belgium · Recruiting
Institut Gustave Roussy
Villejuif, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.